Your browser doesn't support javascript.
loading
A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib.
Santangelo, Alessandra; Rossato, Marzia; Lombardi, Giuseppe; Benfatto, Salvatore; Lavezzari, Denise; De Salvo, Gian Luca; Indraccolo, Stefano; Dechecchi, Maria Cristina; Prandini, Paola; Gambari, Roberto; Scapoli, Chiara; Di Gennaro, Gianfranco; Caccese, Mario; Eoli, Marica; Rudà, Roberta; Brandes, Alba Ariela; Ibrahim, Toni; Rizzato, Simona; Lolli, Ivan; Lippi, Giuseppe; Delledonne, Massimo; Zagonel, Vittorina; Cabrini, Giulio.
Afiliación
  • Santangelo A; Department of Neurosciences, Biomedicine, and Movement, University of Verona, Verona, Italy.
  • Rossato M; Department of Biotechnology, University of Verona, Verona, Italy.
  • Lombardi G; Department of Oncology, Veneto Institute of Oncology (IOV), Scientific Institute for Research, Hospitalization, and Health Care (IRCCS), Padova, Italy.
  • Benfatto S; Department of Biotechnology, University of Verona, Verona, Italy.
  • Lavezzari D; Department of Biotechnology, University of Verona, Verona, Italy.
  • De Salvo GL; Research Unit, IOV-IRCCS, Padova, Italy.
  • Indraccolo S; Basic and Translational Oncology Unit, IOV-IRCCS, Padova, Italy.
  • Dechecchi MC; Department of Neurosciences, Biomedicine, and Movement, University of Verona, Verona, Italy.
  • Prandini P; Department of Neurosciences, Biomedicine, and Movement, University of Verona, Verona, Italy.
  • Gambari R; Department of Life Sciences and Biotechnologies, University of Ferrara, Ferrara, Italy.
  • Scapoli C; Department of Life Sciences and Biotechnologies, University of Ferrara, Ferrara, Italy.
  • Di Gennaro G; Laboratory of Clinical Biochemistry, University Hospital of Verona, Verona, Italy.
  • Caccese M; Department of Oncology, Veneto Institute of Oncology (IOV), Scientific Institute for Research, Hospitalization, and Health Care (IRCCS), Padova, Italy.
  • Eoli M; Molecular Neuro-Oncology Unit, Carlo Besta Neurological Institute Foundation, Milan, Italy.
  • Rudà R; Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, Turin, Italy.
  • Brandes AA; Medical Oncology Department, Local Health Unit, IRCCS Institute of Neurological Sciences, Bologna, Italy.
  • Ibrahim T; Osteo-oncology and Rare Tumors Center, Romagna Scientific Institute for the Study and Treatment of Cancer, IRCCS, Meldola, Italy.
  • Rizzato S; Department of Oncology, Friuli-Venezia Giulia University Hospital, Udine, Italy.
  • Lolli I; Medical Oncology Unit, IRCCS Saverio de Bellis Hospital, Castellana Grotte, Bari, Italy.
  • Lippi G; Department of Neurosciences, Biomedicine, and Movement, University of Verona, Verona, Italy.
  • Delledonne M; Department of Biotechnology, University of Verona, Verona, Italy.
  • Zagonel V; Department of Oncology, Veneto Institute of Oncology (IOV), Scientific Institute for Research, Hospitalization, and Health Care (IRCCS), Padova, Italy.
  • Cabrini G; Department of Neurosciences, Biomedicine, and Movement, University of Verona, Verona, Italy.
Neuro Oncol ; 23(2): 264-276, 2021 02 25.
Article en En | MEDLINE | ID: mdl-32661549
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glioblastoma / MicroARNs Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Neuro Oncol Asunto de la revista: NEOPLASIAS / NEUROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glioblastoma / MicroARNs Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Neuro Oncol Asunto de la revista: NEOPLASIAS / NEUROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido